eIF2C2 Inhibitors
Common eIF2C2 Inhibitors include, but are not limited to Etoposide (VP-16) CAS 33419-42-0, Fluorouracil CAS 51-21-8, Bortezomib CAS 179324-69-7, Cisplatin CAS 15663-27-1 and Actinomycin D CAS 50-76-0.
Eukaryotic translation initiation factor 2C2 (eIF2C2), also widely recognized as Argonaute 2 (Ago2), plays a pivotal role in the RNA-induced silencing complex (RISC) within cells. The RISC is central to the RNA interference (RNAi) pathway, a mechanism responsible for post-transcriptional gene silencing in a sequence-specific manner. eIF2C2/Ago2 emerges as the primary effector protein in this complex, endowed with endonuclease activity, enabling it to cleave target mRNA. Beyond its endonucleolytic capabilities, eIF2C2/Ago2 also functions as a platform, binding to small RNAs, such as microRNAs (miRNAs) and small interfering RNAs (siRNAs). These small RNAs act as guides, directing the eIF2C2/Ago2-containing RISC to complementary sequences on target mRNAs, leading to their subsequent degradation or translational repression.
Inhibitors targeting eIF2C2/Ago2 are molecules designed to modulate the function of eIF2C2/Ago2, impeding its endonucleolytic activity, interaction with small RNAs, or its association with other components of the RISC. Given eIF2C2/Ago2's fundamental role in the RNAi pathway, these inhibitors could have profound effects on post-transcriptional gene regulation. The precise molecular mechanism through which these inhibitors exert their effects can vary. Some might directly bind to eIF2C2/Ago2, altering its conformation and subsequently its functionality. Others might interfere with its interaction with small RNAs, disrupting the RNAi process at its foundational level. The study of eIF2C2/Ago2 inhibitors offers an avenue to understand the intricacies of the RNAi pathway better, elucidating the myriad of molecular interactions that coalesce to regulate gene expression post-transcriptionally. The chemical landscape of these inhibitors remains a dynamic and evolving field, continually expanding as novel compounds are synthesized and characterized.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $51.00 $231.00 $523.00 | 63 | |
Etoposide causes DNA damage, which could lead to a cellular stress response, potentially diverting cellular resources from RNAi pathways and thus down-regulating eIF2C2. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $37.00 $152.00 | 11 | |
By acting as a pyrimidine analog, 5-Fluorouracil might disrupt nucleotide metabolism. This disruption could indirectly affect RNAi components by hampering RNA synthesis, leading to decreased eIF2C2 levels. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib inhibits the proteasome, affecting protein turnover. This can disrupt the balance of cellular proteins, potentially decreasing the stability or synthesis of eIF2C2. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $138.00 $380.00 | 101 | |
Cisplatin's DNA crosslinking might induce a cellular response that shifts focus from typical gene regulation, potentially suppressing RNAi machinery and eIF2C2 expression. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Actinomycin D hinders RNA synthesis by intercalating DNA. This can lead to a general down-regulation of RNA-derived processes, which might include a decrease in eIF2C2 levels. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
By inhibiting protein synthesis, Cycloheximide might halt the production of new eIF2C2 molecules, leading to a net decrease in eIF2C2 as existing proteins degrade. | ||||||
Doxorubicin | 23214-92-8 | sc-280681 sc-280681A | 1 mg 5 mg | $176.00 $426.00 | 43 | |
DNA damage from Doxorubicin may cause the cell to prioritize DNA repair over regular functions, potentially suppressing RNAi machinery and decreasing eIF2C2 levels. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $58.00 $186.00 $94.00 | 21 | |
Camptothecin's inhibition of topoisomerase I can cause DNA damage, which might lead to a reduced focus on RNAi processes and subsequent lower eIF2C2 expression. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
By affecting mTOR signaling, Rapamycin might alter protein synthesis and degradation patterns, potentially leading to reduced eIF2C2 synthesis or increased degradation. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
As a kinase inhibitor, Staurosporine may disrupt signaling pathways related to RNAi machinery stability or synthesis, potentially leading to reduced eIF2C2 levels. | ||||||